Discoid lupus erythematosus
MONDO:0019558A chronic, autoimmune skin condition that manifests with a red, scaling rash, most often found on the face, ears, and scalp; these lesions often lead to permanent scarring and dyspigmentation. Patients may have lesions with or without other symptoms or antibodies suggestive of systemic lupus erythematosus (SLE).
Also known as: DLE
52 clinical trials for this condition and its sub-types, 17 tagged with Discoid lupus erythematosus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control By invitation onlyThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New shot may tame stubborn lupus skin lesions
Disease control OngoingThis study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New lupus drug enpatoran tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…
Phase 2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug could tame lupus skin flares
Disease control OngoingThis phase 2 trial tests deucravacitinib, an anti-inflammatory pill, against a placebo in 74 adults with active discoid or subacute cutaneous lupus — skin rashes caused by lupus. The main goal is to see if the drug reduces rash severity after 16 weeks. Participants must already b…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 15:30 UTC